HAE
Haemonetics Corp.

622
Loading...
Loading...
News
all
press releases
Understanding Haemonetics (HAE) Reliance on International Revenue
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Zacks·26d ago
News Placeholder
More News
News Placeholder
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·30d ago
News Placeholder
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of +8.91% and +5.97%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·30d ago
News Placeholder
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Zacks·1mo ago
News Placeholder
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of +4.17% and +3.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes
Investing.com -- Citi analysts have taken action on two U.S. MedTech names, upgrading Haemonetics (NYSE:HAE) to Buy from Neutral, while downgrading Tandem Diabetes Care (NASDAQ:TNDM) to Sell/High Risk from Neutral/High Risk, citing diverging prospects in the second half of 2025.
investing.com·2mo ago
News Placeholder
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
Investing.com -- Citi analysts revised their MedTech coverage following a volatile first quarter, with several rating changes and adjustments to target prices.
investing.com·4mo ago
News Placeholder
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
chainwire·4mo ago
News Placeholder
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference PR Newswire BOSTON, Feb...
PR Newswire·6mo ago

Latest HAE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.